Accolade, Inc. (NASDAQ:ACCD – Get Free Report)’s share price was down 7.1% during trading on Friday after Canaccord Genuity Group lowered their price target on the stock from $18.00 to $17.00. Canaccord Genuity Group currently has a buy rating on the stock. Accolade traded as low as $7.87 and last traded at $7.87. Approximately 89,422 shares changed hands during trading, a decline of 86% from the average daily volume of 625,301 shares. The stock had previously closed at $8.47.
Other equities research analysts have also recently issued research reports about the stock. Credit Suisse Group lifted their price target on shares of Accolade from $13.00 to $15.00 and gave the stock a “neutral” rating in a report on Friday, June 30th. Stephens reaffirmed an “overweight” rating and issued a $18.00 price target on shares of Accolade in a report on Thursday. Truist Financial lowered their price target on shares of Accolade from $17.00 to $15.00 in a report on Thursday. Bank of America lowered their price target on shares of Accolade from $19.00 to $16.00 in a report on Thursday. Finally, Guggenheim lifted their price target on shares of Accolade from $18.00 to $19.00 in a report on Friday, June 30th. Five analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $15.53.
Get Our Latest Stock Analysis on ACCD
Institutional Inflows and Outflows
Accolade Price Performance
The business’s 50-day moving average price is $12.64 and its 200 day moving average price is $12.94. The stock has a market capitalization of $620.17 million, a PE ratio of -4.25 and a beta of 1.81. The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.09 and a current ratio of 3.09.
Accolade (NASDAQ:ACCD – Get Free Report) last announced its earnings results on Wednesday, October 4th. The company reported ($0.43) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.11. Accolade had a negative net margin of 37.24% and a negative return on equity of 30.03%. The company had revenue of $96.86 million during the quarter, compared to analyst estimates of $94.09 million. During the same period in the previous year, the business earned ($0.66) earnings per share. The firm’s quarterly revenue was up 10.5% compared to the same quarter last year. Research analysts forecast that Accolade, Inc. will post -1.66 earnings per share for the current year.
About Accolade
Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and virtual primary care physicians.
See Also
- Five stocks we like better than Accolade
- What is a Secondary Public Offering? What Investors Need to Know
- Levi Strauss: A Bottom is in for Steady, Stable Dividend Payer
- How to Invest in Pharmaceutical Companies
- Starbucks Is About To Become A Value Play You Can’t Miss
- 3 Small Caps With Big Return Potential
- Intel to Unlock Value By Spinning Off Programmable Chip Unit
Receive News & Ratings for Accolade Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accolade and related companies with MarketBeat.com's FREE daily email newsletter.
